# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $18 price target.
Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and lowers the price target from $54 to $32.
Instil Bio (NASDAQ:TIL) reported quarterly losses of $(2.39) per share which missed the analyst consensus estimate of $(2.23) b...
Jefferies analyst Kelly Shi downgrades Instil Bio (NASDAQ:TIL) from Buy to Hold and raises the price target from $5 to $11.
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Instil Bio (NASDAQ:TIL) with a Buy and maintains $18 price target.
Instil Bio (NASDAQ:TIL) reported quarterly Adj losses of $(1.26) per share which beat the analyst consensus estimate of $(2.85)...
HC Wainwright & Co. analyst Mitchell Kapoor maintains Instil Bio (NASDAQ:TIL) with a Buy, adjusts target to $18 from $2.
Baird analyst Jack Allen reiterates Instil Bio (NASDAQ:TIL) with a Outperform and maintains $54 price target.
Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and lowers the price target from $100 to $54.